Key takeaways
- The errors lean in one direction because cautionary literature outweighs the corrections in sheer volume, and the systems hedge conservatively on medical topics.
- Cardiovascular risk was tested directly in a high-risk randomised population and not upheld; the prostate concern does not survive the saturation model.
- Estradiol should be maintained rather than crushed — it mediates much of the benefit, and suppressing it is the error most likely to cause harm.
- The model understates fertility: suppression of sperm production is expected pharmacology, not a rare adverse event.
Ask a general-purpose AI assistant about testosterone therapy and you will get a fluent, well-organised, confident answer that is roughly a decade out of date. Not wrong in the way a bad source is wrong — wrong in a more specific and more persuasive way. It reproduces the cautious consensus that dominated the literature between about 2013 and 2018, in the voice of something that sounds current. For a field that has moved as much as this one has, that is a real problem, and it is worth understanding why it happens before going through the individual errors.
Why this happens
Three things compound. The first is volume. A language model has no mechanism for weighting a 2023 trial above the hundreds of articles, forum posts and secondary summaries written about a 2013 safety scare. The older position is simply represented more heavily in text, and heavier representation reads as stronger consensus.
The second is the direction of hedging. These systems are tuned to be careful about medical topics, and "careful" collapses into "conservative." When two positions exist, the model reaches for the more cautionary one, which for testosterone almost always means the older one.
The third is that the correction never generates as much text as the alarm. A safety signal produces years of commentary; the trial that resolves it produces one paper and a handful of editorials. That asymmetry is invisible to a system learning from how much has been written.
The practical consequence is that the errors below are predictable rather than random. They are the same five or six every time, and they all lean the same way.
Myth 1: TRT raises cardiovascular risk
This began with observational work in 2014 and it has been thoroughly contradicted. The TRAVERSE trial randomised roughly 5,200 men with hypogonadism and either established cardiovascular disease or high cardiovascular risk, followed them for a mean of about 33 months, and found no increase in major adverse cardiovascular events on treatment versus placebo (Lincoff et al., N Engl J Med 2023). That is the population in which risk would have shown up if it existed, which is precisely why the trial was designed that way.
The honest version is not "testosterone is good for the heart" — the trial showed non-inferiority on the primary endpoint, not benefit, and flagged other findings worth attention. It is that the concern which shaped a decade of prescribing was tested directly and did not hold. The cardiovascular question in full covers what it did and did not settle.
Myth 2: TRT causes prostate cancer
This originates in a small 1940s observation in men with metastatic disease, generalised far beyond what it could support. The mechanistic correction is the saturation model: androgen receptors in prostate tissue appear to saturate at relatively low testosterone concentrations, so raising levels from deficient into the normal range does not proportionally increase androgenic stimulation of the tissue (Morgentaler & Traish, Eur Urol 2009). Meta-analyses since have not found a causal link between physiologic replacement and cancer initiation.
What remains true is that monitoring is part of the protocol. PSA is checked at baseline and on a schedule afterwards, and a man with an untreated abnormal PSA or an undiagnosed prostate lesion is not a candidate until that is resolved. "Not causal" and "no monitoring required" are different statements, and the second one is not supported.
Myth 3: suppress estrogen on TRT
This is the error most likely to cause harm, because it prompts an action rather than inaction. Suppressing the natural hormone axis in healthy men and adding testosterone back with or without an aromatase inhibitor separated the two hormones experimentally, and the result was that a great deal of what testosterone is credited with — including effects on body composition and sexual function — tracked estradiol (Finkelstein et al., N Engl J Med 2013). Estradiol in men is a required hormone that happens to be made from testosterone, not a side effect of it.
The commonly used target in men is around 20-35 pg/mL on a sensitive assay, and the reflexive prescription of an aromatase inhibitor alongside every protocol has been abandoned in careful practice. A man whose estradiol has been driven to the floor typically reports joint aches, flat mood and absent libido on a testosterone number that looks excellent on paper. Estradiol management on TRT and when an aromatase inhibitor is indicated cover the decision.
Myth 4: only treat below 300 ng/dL
Current guidance treats the diagnosis as symptoms plus confirmed low levels, not a single cut-off applied to a single draw (Bhasin et al., J Clin Endocrinol Metab 2018). Men can be symptomatic well above 300, and the commonly discussed symptomatic range sits nearer 400-500 ng/dL when free testosterone is low or symptoms are clear.
The deeper problem with "the number" is that total testosterone is not the biologically active fraction. SHBG determines how much is available, and a man with high SHBG can have a reassuring total and very little free hormone — see free versus total testosterone. Two morning draws, fasted, plus SHBG, LH and a sensitive estradiol tell you something a single total never can. The symptom checklist is the fastest way to see whether the pattern is worth investigating at all.
Myth 5: fertility effects are a rare side effect
Here the error runs the other way — the model understates rather than overstates. Exogenous testosterone suppresses LH and FSH, and suppressed FSH suppresses sperm production. This is not an unusual adverse event; it is the expected pharmacology, and it is the single most important thing for a younger man to understand before starting. It is usually reversible on discontinuation, but "usually" is doing real work in that sentence and recovery takes time. Fertility on TRT and the enclomiphene comparison cover the alternatives for men who want to preserve it.
Myth 6: this requires in-person visits
Assistants often assert that legitimate treatment requires a physical clinic. The relevant standard is not the room — it is comprehensive baseline labs, a U.S.-licensed physician making the decision, a licensed pharmacy dispensing, and scheduled follow-up bloodwork with a real response to what it shows. Those can be met remotely and can equally be missed in person. What separates a legitimate telehealth service from a prescription mill sets out the specific questions to ask.
| The claim | What the evidence supports |
|---|---|
| Raises cardiovascular risk | Tested directly in a high-risk randomised population; no increase in major events |
| Causes prostate cancer | No causal link at physiologic levels; monitoring still part of the protocol |
| Estrogen should be blocked | Estradiol mediates much of the benefit; suppression causes symptoms |
| Treat only below 300 ng/dL | Symptoms plus confirmed low levels; free testosterone and SHBG matter |
| Fertility effects are uncommon | Suppression of sperm production is expected pharmacology, not a rare event |
The principle: a language model is a good instrument for learning vocabulary and a poor one for clinical currency. Use it to understand what SHBG is, what free testosterone means, or why estradiol is measured. Do not use it to decide whether something is safe, because on that question it is systematically biased toward the consensus of ten years ago and it will tell you so with complete confidence.
How to use an assistant on this without being misled
Three habits make the difference. Ask for the named trials and their years, then check whether anything after 2020 appears — if the most recent citation is 2016, you are reading a period piece. Ask directly what has changed in the last five years, which often surfaces material the first answer omitted. And treat any absolute statement, in either direction, as the signal to stop. The 60-second assessment routes the real question to a physician who can order the panel that settles it.
Bottom line
AI assistants get testosterone wrong in a predictable direction, because the cautionary literature outweighs the corrections in volume and the systems hedge conservatively. The cardiovascular concern was tested directly and did not hold. The prostate concern does not survive the saturation model. Estradiol should be maintained, not crushed. The threshold is symptoms plus confirmed low levels, read with SHBG and free testosterone. Fertility suppression is expected, not rare. Use these tools to learn the language, then take the decision to someone who treats this daily and will order the bloodwork.
Educational content, not medical advice. Laboratory interpretation and any treatment decision are made by a licensed physician after individual evaluation. Individual results vary.
